Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

340
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso.

PloS one·2026
Same author

Cost-effectiveness of wastewater-based environmental surveillance for SARS-CoV-2 in Blantyre, Malawi and Kathmandu, Nepal: A model-based study.

PLOS global public health·2025
Same author

Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.

Vaccines·2024
Same author

An Application of an Initial Full Value of Vaccine Assessment Methodology to Measles-Rubella MAPs for Use in Low- and Middle-Income Countries.

Vaccines·2024
Same author

Evaluating the cost and operational context for national human papillomavirus (HPV) vaccine delivery in three regions of Ethiopia.

PLOS global public health·2024
Same author

The cost of typhoid illness in low- and middle-income countries, a scoping review of the literature.

PloS one·2024

Related Experiment Video

Updated: Jun 7, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K

Evaluating potential program cost savings with a single-dose HPV vaccination schedule: a modeling study.

Rose Slavkovsky1, Mercy Mvundura2, Frédéric Debellut3

  • 1Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.

Journal of the National Cancer Institute. Monographs
|November 12, 2024
PubMed
Summary

A single-dose human papillomavirus (HPV) vaccine schedule could significantly reduce costs for immunization programs. This shift enhances affordability and long-term sustainability of HPV vaccination efforts globally.

More Related Videos

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.1K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.6K

Related Experiment Videos

Last Updated: Jun 7, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K
A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.1K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.6K

Area of Science:

  • Immunology
  • Public Health
  • Health Economics

Background:

  • Limited evidence exists on cost savings from the World Health Organization's single-dose human papillomavirus (HPV) vaccine schedule.
  • Modeling the cost implications of the new schedule is crucial for program planning.

Purpose of the Study:

  • To model the delivery and vaccine procurement cost implications of a single-dose human papillomavirus (HPV) vaccine schedule.
  • To assess the economic impact on immunization programs.

Main Methods:

  • Leveraged primary data from a study on HPV vaccine delivery costs in five countries (Ethiopia, Guyana, Rwanda, Sri Lanka, Uganda).
  • Adjusted two-dose schedule cost estimates to model a single-dose schedule, considering activity frequency and vaccine delivery volumes.
  • Estimated costs per dose and per adolescent from a health system perspective in 2019 US dollars.

Main Results:

  • Modeled results indicate an increase in cost per dose but a decrease in cost per adolescent for the full vaccination schedule under a single-dose approach.
  • Financial costs per adolescent decreased by up to 50% under the single-dose schedule, ranging from $4.84 to $12.34.
  • Economic costs per adolescent for the single-dose schedule ranged from $7.86 to $28.53.

Conclusions:

  • A single-dose human papillomavirus (HPV) vaccination schedule offers potential cost savings for immunization programs.
  • Implementing a single-dose schedule can enhance the affordability and sustainability of global HPV vaccination initiatives.